Data Sheet (Cat.No.T26699)

TargetMol

AZ10397767

Chemical Properties



CAS No. : 333742-63-5

Formula: C15H14ClFN4O2S2

Molecular Weight: 400.88

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	AZ10397767 is a potent CXCR2 antagonist (IC50 = 1 nM). AZ10397767 significantly reduced the numbers of infiltrating neutrophils into both in vitro and in vivo tumor models.
Targets(IC50)	Others,CXCR

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.4945 mL	12.4726 mL	24.9451 mL
5 mM	0.4989 mL	2.4945 mL	4.989 mL
10 mM	0.2495 mL	1.2473 mL	2.4945 mL
50 mM	0.0499 mL	0.2495 mL	0.4989 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Tazzyman S, Barry ST, Ashton S, Wood P, Blakey D, Lewis CE, Murdoch C. Inhibition of neutrophil infiltration into A549 lung tumors in vitro and in vivo using a CXCR2-specific antagonist is associated with reduced tumor growth. Int J Cancer. 2011 Aug 15;129(4):847-58. doi: 10.1002/ijc.25987. PubMed PMID: 21328342.

Seaton A, Maxwell PJ, Hill A, Gallagher R, Pettigrew J, Wilson RH, Waugh DJ. Inhibition of constitutive and cxc-chemokine-induced NF-kappaB activity potentiates ansamycin-based HSP90-inhibitor cytotoxicity in castrate-resistant prostate cancer cells. Br J Cancer. 2009 Nov 3;101(9):1620-9. doi: 10.1038/sj.bjc.6605356. PubMed PMID: 19809428; PubMed Central PMCID: PMC2778515.

Wilson C, Maxwell PJ, Longley DB, Wilson RH, Johnston PG, Waugh DJ. Constitutive and treatment-induced CXCL8-signalling selectively modulates the efficacy of anti-metabolite therapeutics in metastatic prostate cancer. PLoS One. 2012;7(5):e36545. doi: 10.1371/journal.pone.0036545. PubMed PMID: 22590561; PubMed Central PMCID: PMC3348872.

Wilson C, Wilson T, Johnston PG, Longley DB, Waugh DJ. Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells. Mol Cancer Ther. 2008 Sep;7(9):2649-61. doi: 10.1158/1535-7163.MCT-08-0148. PubMed PMID: 18790747.